DERM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Journey Medical Corp (DERM) is not a strong buy at the moment for a beginner investor with a long-term focus. Despite positive revenue growth and a favorable analyst rating, the stock's technical indicators are bearish, and the company is facing significant financial challenges, including a sharp decline in net income and EPS. The lack of recent trading signals and weak trading sentiment further support a cautious approach.
The stock is exhibiting bearish technical indicators. The MACD is negatively expanding, RSI is at 9.922 indicating oversold conditions, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 5.29 and 4.516, with resistance at 7.796 and 8.57. The stock has experienced a significant regular market decline of -30.01%, with a slight post-market recovery of 1.60%.
Analysts have raised the price target to $12, citing strong Q4 execution and robust prescription volume growth.
Revenue increased by 18.05% YoY in Q4 2025, and gross margin improved by 13.23%.
Net income dropped to 0, a 100% decline YoY, and EPS fell sharply by -771.43%.
The company missed FY 2025 revenue expectations by $3.05 million.
Bearish technical indicators and weak trading sentiment, with no significant hedge fund or insider activity.
In Q4 2025, revenue grew by 18.05% YoY to $16.08 million, and gross margin improved to 66.17%. However, net income dropped to 0, and EPS declined significantly to -0.47, reflecting financial instability.
B. Riley maintains a Buy rating and raised the price target to $12, citing strong Q4 execution and prescription volume growth. However, the stock's current financial challenges and market performance may limit its near-term upside.
